What Is Informed Consent, and What Should It Actually Include Before a Stem Cell Procedure?

Informed consent is often treated as paperwork — a form to sign on the way to the exam room. In reality, it is a legal and ethical process, and one of the most powerful tools a patient has for staying safe. This is especially true in stem cell medicine, where the same phrase — "informed consent" — can mean two very different things depending on where you are: a rigorous, regulator-reviewed process built around a registered clinical trial or an FDA-approved product, or a thin document at an unproven clinic designed more to protect the clinic than to inform you. This article explains what real informed consent is supposed to include, how it differs across these two settings, and the specific questions and red flags that let you tell them apart.

What Informed Consent Actually Means

Informed consent is the process by which a patient voluntarily agrees to a medical intervention after receiving and understanding enough information to make that decision for themselves. Under the federal regulations that govern research with human subjects — the "Common Rule," codified at 45 CFR 46.116 — a valid consent process must generally disclose: that the procedure involves research and is experimental (if it is), its purpose and duration, its procedures, its reasonably foreseeable risks, its expected benefits, any appropriate alternative treatments, how confidentiality will be handled, and, for anything beyond minimal risk, what compensation or treatment is available if something goes wrong. Consent must also state clearly that participation is voluntary, that refusing involves no penalty, and that the person may withdraw at any time without losing care they're otherwise entitled to.

That last piece — voluntariness — traces back to the Belmont Report, the 1979 ethics framework (from the U.S. National Commission, overseen today by HHS's Office for Human Research Protections) that underlies the Common Rule. It requires that consent be free of coercion and "undue influence," including financial or psychological pressure that could distort a person's judgment.

How This Is Supposed to Work in a Registered Clinical Trial

When a stem cell intervention is being studied in a legitimate, registered clinical trial — one overseen by an Institutional Review Board (IRB) and typically listed on ClinicalTrials.gov — the consent process is built around exactly these Common Rule elements, and an IRB independently reviews the consent form before anyone can be enrolled. You should be told plainly that the treatment is experimental, what is and isn't yet known about it, what the realistic risks and benefits are (not testimonials), what your alternatives are (including approved treatments and doing nothing), and that you're free to leave the study at any point. Well-run trials do not usually charge participants to enroll; the FDA and ISSCR both flag being charged to join a "trial" as a serious warning sign, not a normal cost of research.

Where It Goes Wrong at Unproven Stem Cell Clinics

Many clinics market "stem cell therapy" for conditions like arthritis, autism, or neurological disease using cells that have not been FDA-approved for that use and are not being offered inside a registered trial. The FDA has stated plainly that most regenerative medicine products on the market today are unapproved, and that being charged for such products, or offered them outside a clinical trial, likely means being deceived and offered a product illegally. Currently, FDA-approved stem cell products remain very limited — largely certain cord-blood-derived products for specific blood disorders — and no exosome product has FDA approval.

At these clinics, "informed consent" forms can look reassuring while doing the opposite of what real consent requires: burying or omitting the fact that the product is unapproved and experimental, presenting patient testimonials as if they were evidence of benefit, and sometimes including broad liability waivers that attempt to have patients sign away rights they cannot actually waive. The ISSCR's Informed Consent Standard for Stem Cell-Based Interventions states directly that informed consent is "a necessary, but not a sufficient condition for ethical medical practice" — meaning a signed form never makes an unproven treatment safe or appropriate on its own.

What a Real Consent Process Should Include

Whether you're evaluating a clinical trial or a clinic offering an intervention outside one, ISSCR's consent standard and general medical-ethics practice point to the same core elements a legitimate process should cover:

• Regulatory and evidentiary status — whether the treatment has been approved by a regulator (FDA, EMA, or similar) for your specific condition, and whether supporting evidence is published, peer-reviewed, and independently replicated, versus resting on testimonials
• Specific risks — the nature, likely severity, and estimated probability of each risk, including cell-harvesting or processing complications and long-term unknowns
• Realistic benefits — only claims supportable with scientific evidence, with a clear plan for how outcomes will be monitored
• Alternatives — other proven treatments, and the alternative of enrolling in an approved clinical trial instead
• Costs and conflicts of interest — what you'll pay, what insurance may or may not cover, and any financial interest the provider has beyond a standard fee
• Voluntariness and withdrawal — a clear statement that you can decline or stop at any time without losing access to other care

Red Flags and Questions to Ask

Both the FDA and ISSCR publish patient-facing guidance built around a short set of direct questions. Before agreeing to any stem cell procedure, ask:

1. Has this specific treatment, for this specific condition, been approved by the FDA (or another national regulator)?
2. Is this being offered as part of a registered clinical trial with independent ethics/IRB oversight — and can I verify that listing myself?
3. Can I have a copy of the written consent form in advance, so I can review it at home or with an independent physician?
4. What, specifically, are the risks — not just "minimal" or "low," but named complications and their likelihood?
5. Am I being asked to pay to participate, and is that payment unusually high or required upfront?

Warning signs worth treating seriously: being pressured to decide or sign quickly; a clinic that won't provide the consent form ahead of the visit; reliance on testimonials rather than published data; claims that one cell product treats many unrelated diseases; and any suggestion that regulatory approval "isn't necessary" for what you're being offered.

Verifying a Trial or Product's Real Status

You don't have to take a clinic's word for it. ClinicalTrials.gov lets you search for a study by name, condition, or location and see its actual registration, sponsor, and status. The FDA's Office of Combination Products can be contacted directly to ask whether a specific product has been approved or requires approval. The ISSCR's own patient handbook and clinic-vetting questions are built for exactly this kind of pre-visit check.

Bottom Line

Informed consent, done properly, is not a bureaucratic hurdle — it's a genuine patient protection, and in legitimate stem cell research it comes with real regulatory teeth: independent ethics review, mandated disclosures under the Common Rule, and an explicit right to walk away at any time. The same concept, at an unproven clinic operating outside a registered trial, can be reduced to a document that obscures investigational status or leans on a waiver to shift risk onto you. The difference isn't subtle once you know what to check: ask about FDA approval and trial registration, ask to see the consent form before you arrive, and treat pressure to pay upfront or sign quickly as a reason to slow down, not speed up.